Adjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Cancer

Basit Öğe Kaydı
dc.contributor.authorTuran, Nedim
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorKoca, Dogan
dc.contributor.authorUstaalioglu, Basak Oven
dc.contributor.authorDane, Faysal
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorUlas, Arife
dc.date.accessioned2024-04-24T17:14:28Z
dc.date.available2024-04-24T17:14:28Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: We aimed to investigate the impact of adjuvant systemic therapy with modern chemotherapy combinations on survival outcomes in patients with resected liver-confined metastases from colorectal carcinomas, and whether addition of bevacizumab (BEV) provides further benefit. Methods: A total of 229 consecutive patients who underwent resection for liver-confined colorectal liver metastases were retrospectively analyzed. Results: Of 229 patients, 204 who received chemotherapy with fluoropyrimidine-based (n = 27), irinotecan-based (n = 84) and oxaliplatin-based (n = 93) combinations were analyzed. Among these, 87 patients received BEV while 117 did not (NoBEV). With a median follow-up of 27 months after metastasectomy, the median recurrence-free survival (RFS) and overall survival OS) were 17 and 53 months, respectively. OS rates at 3 and 5 years were 71% and 40%, respectively. No significant differences were found in the median RFS (p = 0.744) and OS (p = 0.440) among different chemotherapy regimens. The median RFS (p = 0.375) and OS (p = 0.251) were similar in BEV and NoBEV arms. In multivariate analysis, having 4 liver metastases was the only negative independent factor on both RFS and OS, while positive surgical margin was another negative independent factor for RFS. Conclusion: Chemotherapy type and addition of BEV have no impact on both RFS and OS in the adjuvant setting following complete resection of colorectal liver metastases. Copyright (C) 2012 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000342429
dc.identifier.endpage21en_US
dc.identifier.issn0030-2414
dc.identifier.issn1423-0232
dc.identifier.issue1en_US
dc.identifier.pmid23076023
dc.identifier.scopus2-s2.0-84867468638
dc.identifier.scopusqualityQ2
dc.identifier.startpage14en_US
dc.identifier.urihttps://doi.org/10.1159/000342429
dc.identifier.urihttps://hdl.handle.net/11468/17970
dc.identifier.volume84en_US
dc.identifier.wosWOS:000310578300003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal Canceren_US
dc.subjectLiver Metastasesen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectBevacizumaben_US
dc.titleAdjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Canceren_US
dc.titleAdjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu